Grifols Initiates Clinical Investigation of New Treatment Protocol for Alzheimer's Disease
The new clinical investigation involves a combined treatment of therapeutic plasmapheresis and the administration of human albumin and intravenous immune globulin (IVIG) at different doses and frequencies. Human albumin and IVIG are two of the main therapeutic plasma proteins Grifols produces from donations of human blood plasma at dedicated donation centers acrossthe United States.
In conjunction with the announcement of the new clinical investigation, Grifols also announced that it has entered into an exclusive design and development agreement with U.S.-based Fenwal, Inc. for the production of a prototype plasmapheresis device specifically adapted for use in Grifols' Alzheimer's research. Fenwal is expected to deliver the first prototype devices at the end of this year. It is anticipated that the 2011 study will take place over the course of two years.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.